57. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Combined estrogen-progestogen contraceptives. Exit Disclaimer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2012; 100A:283–311.

58. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology 2016; 34(24):2888–2898.

59. Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstetrics and Gynecology 2013; 122(1):139–147.

60. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners’ Oral Contraception Study. American Journal of Obstetrics and Gynecology 2017; 216(6):580.e1-580.e9.

61. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(11):1931–1943.

62. Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes & Control 2015; 26(1):65–78.

63. Murphy N, Xu L, Zervoudakis A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Initiative Observational Study. British Journal of Cancer 2017; 116(1):117–125.

64. Vicus D, Finch A, Rosen B. et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.// Gynecol Oncol. 2010 Aug;118(2):155–9. Epub 2010 May 10.

65. Jordan SJ, Green AC, Whiteman DC et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.// Int J Cancer. 2008;122(7):1598.

66. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017):1713–1727.

67. Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Research 2014; 74(15):4078–4089.

68. Hankinson SE, Colditz GA, Manson JE et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States).//Cancer Causes Control. 1997; 8(1):65.

69. Vessey M, Painter R Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004.// Br J Cancer. 2006; 95(3):385. Epub 2006 Jul 4.

70. Vessey M, Yeates D Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study // Contraception. 2013 Dec; 88(6):678–83. Epub 2013 Sep 2.

71. Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer.// N Engl J Med. 2002;346(26):2025.

72. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine 2017; 377(23):2228–2239.

73. Moorman PG, Havrilesky LJ, Gierisch JM et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.// J Clin Oncol. 2013 Nov;31(33):4188-98. Epub 2013 Oct 21.

74. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer 2010; 46(12):2275–2284.

75. McLaughlin JR, Risch HA, Lubinski J. et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.// Lancet Oncol. 2007;8(1):26.

76. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364):1159–1167.

77. Moreno V, Bosch FX, Muñoz N. et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.// Lancet. 2002;359(9312):1085.

78. Gierisch JM, Coeytaux RR, Urrutia RP et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.// Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1931-43. Epub 2013 Sep 6.

79. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370(9599):1609–1621.

80. Радзинский В. Е. и др. Фактология «искренних заблуждений». Отношение российских врачей к гормональной контрацепции / В. Е. Радзинский, М. Б. Хамошина // Status Praesens. 2011. № 3. С. 16–19.

81. Peterson K. B. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan // Human Reproduction. 2015. Vol. 30. № 10. P. 2364–2375.

82. Cronin M. et al. Rate of pregnancy after using drospirenone and other progestincontaining oral contraceptives. Obstetrics & Gynecology, 2009. Vol. 114 (3). P. 616–22.

83. Андреева Е.Н., Соколова Д.А., Григорян О.Р. Контрацепция у женщин с ожирением. Ожирение и метаболизм. 2016; 13(3):65–69.

84. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thrombosis and Haemostasis. Mar 2003; 89(3):493–498.

85. Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) 2016.

86. Асташкин Е.И., Глезер М.Г. Ожирение и артериальная гипертония // Проблемы женского здоровья. № 4. Т. 3. 2008.

87. Arbeeny C.M. Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res 2004; 12(8): 1191–6.

88. Sharp HT, Adelman M. 2017 Update on abnormal uterine bleeding. Endometrial sampling and obesity: Forget the «age 45» rule. OBG Manag 2017 April;29(4):30–36.

89. National Collaborating Centre for Women’s and Children’s Health. Heavy Menstrual Bleeding Clinical Guideline 44. London: RCOG Press for NICE; 2007.

Глава 4. LARC – контрацепция для ленивых

1. The American College of Obstetricians and Gynecologists. Long-acting reversible contraception: implants and intrauterine devices. PB. 2017. Number 186.

2. Jeffrey F Peipert, Qiuhong Zhao, Jenifer E Allsworth, Emiko Petrosky, Tessa Madden, David Eisenberg, Gina Secura. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105-13. doi: 10.1097/AOG.0b013e31821188ad.